Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Meeting Abstract
| Authors: | Sharma, M.; Dumbrava, E. I.; Carvajal, R.; Catenacci, D.; Emens, L.; Hanna, G.; Juric, D.; Kang, Y. K.; Lee, J.; Lee, K. W.; Li, B.; Moore, K.; Pegram, M.; Pohlmann, P.; Rasco, D.; Spira, A.; Tan, A.; Wang, D.; Ackerman, S.; LeBlanc, H.; Dornan, D.; Kowanetz, M.; Alonso, M.; Perez, E.; Perez, E. |
| Abstract Title: | Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors |
| Meeting Title: | 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Nov 9-14 |
| Meeting Location: | Virtual |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-11-01 |
| Start Page: | A244 |
| Language: | English |
| ACCESSION: | WOS:000616665300390 |
| DOI: | 10.1136/jitc-2020-SITC2020.0401 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 401 -- Source: Wos |
